Semaglutide injection versus WEGOVY® for weight loss in Chinese adults with obesity
Official title: A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection and WEGOVY® in Chinese Obese Patients
Run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07036172 · Data updated 2026-11-12
This 48-week test compares a semaglutide injection made by Hangzhou Zhongmei with WEGOVY® to see if it helps Chinese adults with obesity lose weight and is similarly safe.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 460 (estimated) |
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | January 3, 2025 |
| Main results expected | April 2026 |
| Study ends | May 2026 |
| Registry record updated | June 25, 2025 |
| Trial ID | NCT07036172 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults in China aged 18–75 with a BMI of at least 28 kg/m2, without type 1 or type 2 diabetes, who have had no more than a 5% weight change in the prior 90 days and can attend clinic visits in Beijing are ideal candidates.
✕Probably not a fit
People with diabetes, recent major cardiovascular events, a history of pancreatitis, certain thyroid cancers or MEN2, recent malignancy, or significant psychiatric disorders are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, open-label, parallel-controlled Phase 3 study compares an investigational semaglutide injection (HDM1702) with WEGOVY® in Chinese adults with obesity over 48 weeks. Participants are randomized 1:1 to receive once-weekly injections for 44 weeks followed by a 4-week safety follow-up, and all receive lifestyle counseling on diet and physical activity. The trial will measure weight loss, safety outcomes, and immunogenicity to determine biosimilarity between the two products. Key eligibility includes age 18–75, BMI ≥28 kg/m2, no history of diabetes, and stable weight in the prior 90 days.
Why it matters
Potential benefit: If successful, the investigational semaglutide could provide a similarly effective and safe alternative to WEGOVY® and potentially improve access or reduce cost for people with obesity.
How similar studies have gone: Large trials of branded semaglutide (WEGOVY®) have demonstrated substantial weight loss, but direct biosimilar Phase 3 comparisons are less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female, aged ≥18 years and ≤75 years at the time of signing informed consent； 2. BMI ≥28 kg/m2； 3. A self-reported change in body weight no more than 5% within 90 days before screening. Exclusion Criteria: 1. History of type 1 and type 2 diabetes; 2. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device; 3. History or presence of chronic or acute pancreatitis; 4. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma; 5. A history or presence of suspected depression or other mental disorders; 6. Patient Health Questionnaire-9 score of ≥15 at screening 7. Uncontrolled hypertension, any of the following: myocardial infarction, stroke, hospitalisation for unstable angina, or transient ischaemic attack within the past 6 months prior to screening; 8. History of malignant neoplasms within the past 5 years prior to screening;
Where it's running
-
Peking University People's Hospital
Beijing, China Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.